- Home
- LWLG vs CHRS Comparison
LWLG vs CHRS Comparison
Compare LWLG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWLG
- CHRS
- Stock Information
- Founded
- LWLG 1991
- CHRS 2010
- Country
- LWLG United States
- CHRS United States
- Employees
- LWLG N/A
- CHRS N/A
- Industry
- LWLG Containers/Packaging
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LWLG Industrials
- CHRS Health Care
- Exchange
- LWLG Nasdaq
- CHRS Nasdaq
- Market Cap
- LWLG 126.0M
- CHRS 102.0M
- IPO Year
- LWLG N/A
- CHRS 2014
- Fundamental
- Price
- LWLG $2.64
- CHRS $1.04
- Analyst Decision
- LWLG
- CHRS Buy
- Analyst Count
- LWLG 0
- CHRS 3
- Target Price
- LWLG N/A
- CHRS $4.68
- AVG Volume (30 Days)
- LWLG 2.7M
- CHRS 1.3M
- Earning Date
- LWLG 08-08-2025
- CHRS 08-07-2025
- Dividend Yield
- LWLG N/A
- CHRS N/A
- EPS Growth
- LWLG N/A
- CHRS N/A
- EPS
- LWLG N/A
- CHRS N/A
- Revenue
- LWLG $88,105.00
- CHRS $272,251,000.00
- Revenue This Year
- LWLG N/A
- CHRS N/A
- Revenue Next Year
- LWLG N/A
- CHRS $99.43
- P/E Ratio
- LWLG N/A
- CHRS $2.44
- Revenue Growth
- LWLG 24.23
- CHRS 19.87
- 52 Week Low
- LWLG $0.79
- CHRS $0.66
- 52 Week High
- LWLG $4.23
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- LWLG 82.13
- CHRS 68.96
- Support Level
- LWLG $1.75
- CHRS $0.88
- Resistance Level
- LWLG $2.85
- CHRS $1.06
- Average True Range (ATR)
- LWLG 0.24
- CHRS 0.07
- MACD
- LWLG 0.13
- CHRS 0.02
- Stochastic Oscillator
- LWLG 87.12
- CHRS 93.38
About LWLG Lightwave Logic Inc.
Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.